Navigation Links
ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
Date:11/4/2010

RANCHO CORDOVA, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it has signed a distribution agreement covering China and Hong Kong for its products used to prepare cell concentrates, including stem cells, from bone marrow, at the point-of-care and in the laboratory.

The four-year agreement is with Nanshan Memorial Medical Institute (Nanshan), a progressive regenerative medicine company in China and Hong Kong that distributes medical products and has operated multiple, large healthcare facilities, including hospitals, stem cell banks and research centers. Under the agreement, Nanshan will have exclusive distribution rights for the Company's Res-Q™ 60 BMC (Res-Q) System and the MXP™ MarrowXpress products.

Dr. Lu Daopei is founder and serves as medical director on behalf of Nanshan. Dr. Lu is a world-renowned hematologist and expert in the field of hematopoietic stem cell transplants. He pioneered the first successful syngeneic bone marrow stem cell transplant in the People's Republic of China to treat aplastic anemia and the first allogeneic peripheral blood stem cell transplant to treat acute leukemia.

"This agreement represents a major milestone in our strategy to expand the geographic reach of our offerings into a very exciting market opportunity for the Company," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis. "We believe Dr. Lu's reputation as a pioneer in hematological medicine and leading stem cell expert in China, combined with the strong, in-country presence of Nanshan, will greatly enhance ThermoGenesis' ability to achieve timely government approvals and market adoption of our bone marrow technologies," he added.  

During phase one of the distribution agreeme
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
2. ThermoGenesis Announces National Institute of Health Grant
3. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
4. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
6. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
7. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
8. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
10. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... to the new market research report “Micro Irrigation System ... by MarketsandMarkets, global micro irrigation system market expected to ... 2010 and is expected to reach $3,414.7 million by ... to 2016. , Browse:, , 150 ... 370 pages and in-depth Table Of Content ...
(Date:5/24/2013)... 24, 2013 Just about any bodyweight training ... Whitfield, a trainer based in Dallas, GA that uses a ... one pushup that is not used enough. , “The ... the standard pushup more challenging. By keeping your hands on ... the abs are being worked much harder than a standard ...
(Date:5/24/2013)... 2013 Child safety expert and author, ... end-of-year gifts for teachers that can "show appreciation for ... Van der Zande is the founder of Kidpower, a ... whose mission is to help people create cultures ... have an incredible impact on the emotional and physical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Patients who ... more likely to suffer from gastroesophageal reflux disease or ... reported in a study published today. , The article, ... Proximal Exposure as Measured by Hypopharyngeal Multichannel Intraluminal Impedance” ... could be of great importance to individuals who live ...
(Date:5/24/2013)... BroadConnect Telecom, the nation’s leading ... IT security solutions, present small to midsized businesses ... more than fifty percent (when compared to conventional ... Bundle Pricing. BroadConnect’s hosted Voice solutions are putting ... , Starting today, until the end of June ...
Breaking Medicine News(10 mins):Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 3Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 4Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers 2
... has come out with a warning to consumers and health care ... Teq, to infants. There is reportedly a risk of intussusception. ... months of age, in three doses as an optional vaccine to ... at times, fatal. , The reporting of 28 cases ...
... lung cancer has won $ 1 million in a lottery. Wayne ... inoperable lung cancer. ,Doctors have given him a year ... he has won this lottery. But the irony that is accompanying ... annual installments over twenty years. ,Schenk is a chain ...
... University in Chicago claim that men who have undergone ... type// of dementia. This study was published in Cognitive ... on 106 men. Out of this, 25 developed a ... undergone vasectomy. According to the chief scientist of this ...
... A new study suggests that patients who develop ... family history includes alcohol// abuse may be more ... effect of medications used to treat their condition. ... shopping, hypersexuality, binge eating and pathological gambling—have been ...
... sclerosis (MS) for 10 years and have few of the disabling ... and that their symptoms will likely not ever occur to the ... that unfortunately this may not be correct. ,After ... whose MS was benign at 10 years, according to the study. ...
... screening has increased, there are still significant disparities in ... of these disparities are by ethnicity, sex, age, education ... the third most common cancer affecting men and women ... in 2005, according to background information in the article. ...
Cached Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
... ENDOPATH Dilating Tip Trocar is a full-featured trocar ... a spring-loaded blade shield. The shield is designed ... internal structures from puncture or laceration once the ... integrated stability sleeve option is designed to enhance ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: